Oramed Pharmaceuticals Inc.

Regulatory Filings • Feb 4, 2018

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person KIDRON NADAV (Last) (First) (Middle) 12 ELIEZER HAGADOL ST. (Street) JERUSALEM L3 9359038						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] 3. Date of Earliest Transaction (Month/Day/Year) 01/31/2018 4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X X Director 10% Owner Officer (give title Other (specify X below) below) President and CEO 6. Individual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction 1. Title of Security (Instr. 3) Date (Month/Day/Year)						2A. Deemed Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned			3. Transaction Code (Instr. 8) Code	V	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) (A) or Amount (D)			Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction 3A. Deemed Date (Month/Day/Year) if any		4. Execution Date, (Month/Day/Year) 8) Code		(e.g., puts, calls, warrants, options, convertible securities) 5. Number Transaction of Code (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) V (A) (D)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Date		7. Title and Amount of Securities Underlying Derivative and 4) Expiration Title		Security (Instr. 3 Amount or Number of Shares		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	\$8.14	01/31/2018			A		97,000		(1)		01/31/2028	Common Stock	97,000		\$0	97,000		D

Explanation of Responses:

1. The Stock Option will vest in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.

/s/ Nadav Kidron 02/02/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

hours per response: 0.5